Abstract Background Intestinal ultrasound (IUS) has been integrated into inflammatory bowel disease (IBD) practice outside of the UK for several years. The NHS has been slow to adopt this and there is ongoing scepticism with regards to its utility. Methods We performed a retrospective service evaluation to demonstrate the utility of IUS in the NHS. IUS was requested additionally to tests performed as standard of care to enable internal audit. We assessed the proportion of cases where IUS altered decision making. Secondary outcomes included the additional value of IUS to faecal calprotectin (fcal) and the accuracy of IUS in terms of the presence, activity and extent of disease. Similar to the METRIC study,1 IUS accuracy was determined after accounting for all available investigations performed in each patient and recorded as a binary outcome. Where pathology was missed, changes in management were recorded. Data collected included demographic, disease phenotype, body mass index, pregnancy, indication for IUS and scan adequacy. Results We performed 74 IUS on patients with: Crohn’s disease (53) [L1–40; L3–13; B1–11; B2–32; B3–10; p1], ulcerative colitis (17) [E1–2; E2–5; E3–10] and suspected CD (4). Mean age 45.5 years; 45 (61%) female, mean BMI 25.2, pregnant [mean 29/40 weeks] 7 (9.4%). Indications included disease flare (34, 46%), asymptomatic with raised fcal (4, 5%) or disease monitoring (36, 49%). In total, 10 (13%) were deemed inadequate due to (gravid uterus obscuring view [3, 4%), BMI >26 (4, 5%), difficult scan (3, 4%). All 10 patients had mild (6, 8%) or quiescent disease (4, 5%). Table 1 shows the outcomes of the remaining 64 scans. In 52/64 (81%) cases the IUS altered immediate treatment decisions. In 38/64 cases, the IUS added additional value compared to using the subsequently resulted fcal alone. The presence, activity and extent of disease was concordant with standard tests (92%, 92% and 62% of cases, respectively). Missed pathology requiring alternative treatment was identified in 6/63 (9.5%) cases (mild aphthous ulceration seen on VCE [normal MRE] [4], lymphoma [1] and ileorectal anastomotic stricture [1]). The latter two cases required cross-sectional imaging irrespective of the IUS result. Time to definitive treatment decision was reduced by an average of 57 (24-92) days. Conclusion Despite limited experience in IUS, our outcomes are similar to results from the METRIC trial. The NHS should expedite the adoption of IUS to avoid invasive/expensive tests, add value to the clinical consultation and streamline IBD care. References Taylor SA, Mallett S, Bhatnagar G, et al. Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn’s disease (METRIC): a multicentre trial. Lancet Gastroenterol Hepatol 2018;3(8):548-558. (In eng). DOI: 10.1016/s2468-1253(18)30161-4.
Read full abstract